We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026
20 Aug 2026 - 22 Aug 2026

Growing Safety Problems of Heart-Device Implants

By HospiMedica staff writers
Posted on 27 Aug 2001
A study has found that safety alerts or recall notices on pacemakers or implantable cardioverter-defibrillators (ICDs) have been increasing since 1995, with more than 500,000 of U.S. More...
devices affected by safety alerts or recalls between 1990 and 2000. Moreover, the number of alerts and recalls is expected to continue to grow, according to researchers at Brigham and Women's Hospital (Boston, MA, USA). The study was published in the August 15, 2001, issue of The Journal of the American Medical Association (JAMA).

Although pacemakers comprise more than 75% of such devices, the rate of alerts and recalls is much higher for ICDs, which accounted for 75% of the US$870 million cost of the advisories between 1990 and 2000. The researchers say the increase in advisories may be caused by increased scrutiny on the part of the U.S. Food and Drug Administration (FDA) and also by the fact that the newer devices offer new features and are more complex than previous devices. More than 50% of recalls and alerts are hardware advisories, usually caused by manufacturing defects. The rest are firmware advisories, caused by programming problems. Fortunately, few deaths have been determined to have been caused by malfunction of the devices.

The researchers express the hope that the remarkable technologic advances made in pacemakers and ICDs will be accompanied by a similarly strong effort by manufacturers and the FDA to improve the safety of the devices and thereby reduce the recall rate. In a separate article in JAMA, Kim A. Eagle, M.D., advises three system changes that could help solve the safety problem. These are to require longer periods of preapproval testing and surveillance, to involve non-industry representatives in regulatory oversight, and to devise a tracking system involving parties other than industry alone. Dr. Eagle is with the division of cardiovascular disease, University of Michigan Medical Center (Ann Arbor, USA).

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Glucose Meter
StatStrip®
Wound Irrigation Solution
Prontosan®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.